No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BIOR Biora Therapeutics
- 0.6150
- +0.0155+2.59%
Close Apr 19 16:00 ET
- 0.6268
- +0.0118+1.92%
Post 19:47 ET
22.00MMarket Cap-78P/E (TTM)
0.6200High0.6000Low105.74KVolume0.6000Open0.5995Pre Close64.38KTurnover0.65%Turnover RatioLossP/E (Static)35.77MShares6.700052wk High-0.22P/B9.94MFloat Cap0.585052wk Low--Dividend TTM16.16MShs Float398.0000Historical High--Div YieldTTM3.34%Amplitude0.5850Historical Low0.6080Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share
Biora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery Innovations
Biora Therapeutics Files to Sell 10.7M Common Shares for Holders
Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company's BioJet platform for oral, sy
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development
Mean Plasma Tofacitinib Concentration Following administration of a single oral dose of 5 mg and 10 mg BT-600All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug deliver
Press Release: Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: B
Comments
News
$Biora Therapeutics(BIOR.US$ Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
Benzinga· 2 mins ago
Benzinga· 2 mins ago
2
Update
$Biora Therapeutics(BIOR.US$ Press Release: Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Dow Jones· 1 min ago
Dow Jones· 1 min ago
1
8
Cool! Like! Now need some data release dates!
$Biora Therapeutics(BIOR.US$ performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial
Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood
Remainder of BT-600 clinical trial progressing well and on schedule
Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood
Remainder of BT-600 clinical trial progressing well and on schedule
1
$Biora Therapeutics(BIOR.US$ up tomorrow with good news
1
The CFO of Biora Therapeutics, Eric d'Esparbes, expressed confidence in the company's progress towards optimizing its capital structure and developing its therapeutics programs. The recent transactions are seen as a strong indication of investors' continued confidence in Biora's programs.
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg